Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $5.0 million.

  • Century Therapeutics' Prepaid Assets fell 3719.13% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 3719.13%. This contributed to the annual value of $4.8 million for FY2024, which is 1181.86% up from last year.
  • Per Century Therapeutics' latest filing, its Prepaid Assets stood at $5.0 million for Q3 2025, which was down 3719.13% from $4.3 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Prepaid Assets high stood at $7.9 million for Q3 2024, and its period low was $3.7 million during Q1 2022.
  • For the 4-year period, Century Therapeutics' Prepaid Assets averaged around $5.1 million, with its median value being $4.6 million (2022).
  • Its Prepaid Assets has fluctuated over the past 5 years, first skyrocketed by 8811.34% in 2024, then plummeted by 4215.72% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Prepaid Assets stood at $4.0 million in 2022, then increased by 6.32% to $4.3 million in 2023, then rose by 11.82% to $4.8 million in 2024, then increased by 4.22% to $5.0 million in 2025.
  • Its Prepaid Assets stands at $5.0 million for Q3 2025, versus $4.3 million for Q2 2025 and $4.5 million for Q1 2025.